Two year results of a clinical trail involving pembrolizumab for treating relapsed hodgkin lymphoma.
Home / Resource Library / Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma
Two year results of a clinical trail involving pembrolizumab for treating relapsed hodgkin lymphoma.